Overview
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis
Status:
Active, not recruiting
Active, not recruiting
Trial end date:
2022-02-01
2022-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to determine whether oral etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Arena Pharmaceuticals
Criteria
Inclusion criteria:1. Diagnosed with ulcerative colitis (UC) ≥ 3 months prior to screening
2. Active UC confirmed by endoscopy
Exclusion criteria:
1. Severe extensive colitis
2. Diagnosis of Crohn's disease (CD) or indeterminate colitis or the presence or history
of a fistula consistent with CD
3. Diagnosis of microscopic colitis, ischemic colitis, or infectious colitis